• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用于治疗多重耐药人类免疫缺陷病毒的依巴利珠单抗治疗后乙肝再激活

Reactivation of Hepatitis B After Ibalizumab Therapy for Multidrug-Resistant Human Immunodeficiency Virus.

作者信息

Kaplan Alyson, DeHaan Elliott, Maltz Charles

机构信息

Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell School of Medicine, New York Presbyterian, New York, NY.

Division of Infectious Disease, Department of Medicine, Weill Cornell School of Medicine, New York Presbyterian, New York, NY.

出版信息

ACG Case Rep J. 2021 May 19;8(5):e00594. doi: 10.14309/crj.0000000000000594. eCollection 2021 May.

DOI:10.14309/crj.0000000000000594
PMID:34549064
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8443835/
Abstract

Despite the decreasing morbidity associated with the human immunodeficiency virus (HIV), a large percentage of persons with HIV have at least 1 drug resistance mutation. Ibalizumab, a recently approved drug, targets multidrug-resistant HIV. We present a case of reactivation of hepatitis B after initiation of ibalizumab therapy.

摘要

尽管与人类免疫缺陷病毒（HIV）相关的发病率在下降，但很大一部分HIV感染者至少有1种耐药突变。最近获批的药物依巴利珠单抗可靶向多重耐药的HIV。我们报告了1例依巴利珠单抗治疗开始后乙型肝炎再激活的病例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b243/8443835/efb7dab8e978/ac9-8-e00594-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b243/8443835/efb7dab8e978/ac9-8-e00594-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b243/8443835/efb7dab8e978/ac9-8-e00594-g001.jpg

相似文献

1
Reactivation of Hepatitis B After Ibalizumab Therapy for Multidrug-Resistant Human Immunodeficiency Virus.用于治疗多重耐药人类免疫缺陷病毒的依巴利珠单抗治疗后乙肝再激活
ACG Case Rep J. 2021 May 19;8(5):e00594. doi: 10.14309/crj.0000000000000594. eCollection 2021 May.
2
Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection.挽救治疗包括膦甲酸钠和ibalizumab 用于治疗多种药物耐药的人类免疫缺陷病毒 2 型感染。
Clin Infect Dis. 2024 Apr 10;78(4):1005-1010. doi: 10.1093/cid/ciad695.
3
Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.伊巴利珠单抗治疗多重耐药 HIV-1 的 3 期研究。
N Engl J Med. 2018 Aug 16;379(7):645-654. doi: 10.1056/NEJMoa1711460.
4
Ibalizumab for the treatment of multidrug-resistant HIV-1 infection.伊巴利珠单抗用于治疗多重耐药HIV-1感染。
Drugs Today (Barc). 2019 Jan;55(1):25-34. doi: 10.1358/dot.2019.55.1.2895651.
5
Ibalizumab.依巴斯汀
Curr Opin HIV AIDS. 2018 Jul;13(4):354-358. doi: 10.1097/COH.0000000000000473.
6
Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection.依巴斯汀，一种新型单克隆抗体，用于治疗多重耐药性 HIV-1 感染。
Antimicrob Agents Chemother. 2019 May 24;63(6). doi: 10.1128/AAC.00110-19. Print 2019 Jun.
7
The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States.伊巴利珠单抗在美国成人多重耐药 HIV-1 感染者中的成本效果和预算影响。
Pharmacoeconomics. 2021 Apr;39(4):421-432. doi: 10.1007/s40273-020-00992-6. Epub 2021 Feb 3.
8
Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients.依巴珠单抗和福斯特韦在治疗经过大量前期治疗的HIV感染患者中的应用
Recent Pat Antiinfect Drug Discov. 2018;13(3):190-197. doi: 10.2174/1574891X13666181031120019.
9
Insight into the modified Ibalizumab-human CD4 receptor interactions: using a computational binding free energy approach.深入了解修饰后的依巴珠单抗与人类CD4受体的相互作用：采用计算结合自由能方法。
J Comput Aided Mol Des. 2015 Jan;29(1):69-78. doi: 10.1007/s10822-014-9805-4. Epub 2014 Oct 24.
10
Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy.靶向CD4受体的依巴利珠单抗，一种HIV治疗中的新兴分子。
Front Microbiol. 2017 Nov 27;8:2323. doi: 10.3389/fmicb.2017.02323. eCollection 2017.

引用本文的文献

1
Current drugs for HIV-1: from challenges to potential in HIV/AIDS.当前用于治疗HIV-1的药物：从HIV/AIDS面临的挑战到潜在应用
Front Pharmacol. 2023 Oct 26;14:1294966. doi: 10.3389/fphar.2023.1294966. eCollection 2023.

本文引用的文献

1
2019 update of the drug resistance mutations in HIV-1.2019年人类免疫缺陷病毒1型耐药性突变的更新情况。
Top Antivir Med. 2019 Sep;27(3):111-121.
2
Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection.依巴斯汀，一种新型单克隆抗体，用于治疗多重耐药性 HIV-1 感染。
Antimicrob Agents Chemother. 2019 May 24;63(6). doi: 10.1128/AAC.00110-19. Print 2019 Jun.
3
Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy.靶向CD4受体的依巴利珠单抗，一种HIV治疗中的新兴分子。
Front Microbiol. 2017 Nov 27;8:2323. doi: 10.3389/fmicb.2017.02323. eCollection 2017.
4
Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.接受抗癌治疗的血液系统恶性肿瘤患者中乙型肝炎病毒再激活的预防与管理
World J Gastroenterol. 2016 Jul 28;22(28):6484-500. doi: 10.3748/wjg.v22.i28.6484.
5
Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?美国食品药品监督管理局近期就免疫抑制药物和抗癌药物引发的乙型肝炎再激活发出警告：这只是冰山一角吗？
Hepatology. 2015 Feb;61(2):703-11. doi: 10.1002/hep.27609.
6
Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.人类免疫缺陷病毒 1 型包膜蛋白可变区 5 中 N-连接糖基化位点的缺失与对 CD4 抗体ibalizumab 的耐药性有关。
J Virol. 2011 Apr;85(8):3872-80. doi: 10.1128/JVI.02237-10. Epub 2011 Feb 2.
7
HIV-1 entry inhibitors: an overview.HIV-1 进入抑制剂：概述
Curr Opin HIV AIDS. 2009 Mar;4(2):82-7. doi: 10.1097/COH.0b013e328322402e.
8
Acute exacerbations of chronic hepatitis B are rarely associated with superinfection of hepatitis B virus.慢性乙型肝炎急性加重很少与乙型肝炎病毒重叠感染相关。
Hepatology. 2001 Oct;34(4 Pt 1):817-23. doi: 10.1053/jhep.2001.28188.
9
Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy.接受高效抗逆转录病毒治疗的患者中，乙肝病毒复制再激活并伴有急性肝炎。
Clin Infect Dis. 2001 Jan;32(1):144-8. doi: 10.1086/317535. Epub 2000 Dec 13.
10
In vivo administration to rhesus monkeys of a CD4-specific monoclonal antibody capable of blocking AIDS virus replication.对恒河猴进行体内给药，给予一种能够阻断艾滋病病毒复制的CD4特异性单克隆抗体。
AIDS Res Hum Retroviruses. 1993 Mar;9(3):199-207. doi: 10.1089/aid.1993.9.199.